The latest report by IMARC Group, titled “Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, offers a comprehensive analysis of the industry, which comprises insights on the global vaccine adjuvants market growth. The market size reached US$ 884 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,812 Million by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.
Vaccine adjuvants, in the realm of immunology and healthcare, play a pivotal role in enhancing the effectiveness of vaccines. These specialized substances are formulated to augment the body’s immune response to a vaccine, ensuring a more robust and lasting defense against diseases. Vaccine adjuvants are designed to work in tandem with vaccines, making them a critical component in the field of vaccination. They also serve as catalysts, bolstering the body’s ability to recognize and combat pathogens, ultimately leading to improved vaccine efficacy.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/vaccine-adjuvants-market/requestsample
Vaccine Adjuvants Market Trends and Drivers:
The market is driven by the increasing emphasis on preventive healthcare and the urgency to combat emerging infectious diseases. In addition to this, a growing aging population worldwide is contributing to the rising demand for vaccines. As older individuals often have weaker immune responses, the need for effective adjuvants to boost vaccine potency becomes paramount. This demographic shift is fostering a favorable environment for vaccine adjuvant manufacturers and developers. Furthermore, advancements in vaccine technology are fueling the adoption of adjuvants. Novel vaccine formulations, including subunit, conjugate, and mRNA vaccines, are becoming more prevalent. Vaccine adjuvants are integral to these formulations, enhancing their effectiveness. This trend is particularly relevant as vaccine research explores new horizons beyond traditional live attenuated and inactivated vaccines. Moreover, regulatory support and approvals are playing a pivotal role in market growth. Regulatory agencies are recognizing the importance of vaccine adjuvants in vaccine development and are streamlining approval processes. This is fostering innovation and competition within the market, as companies strive to meet stringent regulatory requirements.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Product Type:
- Adjuvant Emulsions
- Pathogen Components
- Particulate Adjuvants
- Combination Adjuvants
- Others
Breakup by Route of Administration:
- Oral
- Intramuscular
- Intranasal
- Subcutaneous
- Intradermal
- Others
Breakup by Diseases:
- Cancer
- Infectious Diseases
- Others
Breakup by Application:
- Research
- Commercial
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Adjuvance Tecchnologies Inc.
- Adjuvatis
- Agenus Inc.
- Brenntag SE
- Chemtrade Logistics Inc.
- CSL Limited
- Croda International Plc
- Invivogen
- Novavax Inc.
- OZ Biosciences
- Virometix AG
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
